Breaking News Instant updates and real-time market news.

FNSR

Finisar

$19.30

-0.51 (-2.57%)

, AAPL

Apple

$171.70

-0.97 (-0.56%)

09:21
12/13/17
12/13
09:21
12/13/17
09:21

On The Fly: Pre-market Movers

HIGHER: Finisar (FNSR), up 25% after Apple (AAPL) awarded the company $390M from its $1B Advanced Manufacturing Fund. Apple is up marginally... Limelight Networks (LLNW), up 1.7% after announcing fiscal 2018 guidance... Western Digital (WDC), up 3.4% after confirming a settlement agreement with Toshiba (TOSBF, TOSYY). DOWN AFTER EARNINGS: Verifone (PAY), down 7.4%... MongoDB (MDB), down 5.5%... Civitas (CIVI), down 5.6%... Arrowhead Pharmaceuticals (ARWR), down 2.5%. ALSO LOWER: Eli Lilly (LLY), down just under 1% after announcing guidance for FY17 and FY18... TD Ameritrade (AMTD), down 2.1% after its 27.7M share Spot Secondary priced at $51.50... Nordic American Tanker (NAT), down 23.4% after its 36.37M share Spot Secondary priced at $2.75.

FNSR

Finisar

$19.30

-0.51 (-2.57%)

AAPL

Apple

$171.70

-0.97 (-0.56%)

LLNW

Limelight Networks

$4.67

-0.02 (-0.43%)

WDC

Western Digital

$81.77

0.57 (0.70%)

PAY

Verifone

$18.47

(0.00%)

MDB

MongoDB

$29.00

2.14 (7.97%)

CIVI

Civitas Solutions

$19.80

(0.00%)

ARWR

Arrowhead

$3.55

0.04 (1.14%)

LLY

Eli Lilly

$86.71

(0.00%)

AMTD

TD Ameritrade

$52.69

0.61 (1.17%)

NAT

Nordic American Tankers

$3.67

(0.00%)

  • 13

    Dec

  • 14

    Dec

  • 18

    Jan

  • 31

    Jan

  • 09

    Mar

  • 13

    Dec

FNSR Finisar
$19.30

-0.51 (-2.57%)

12/13/17
PIPR
12/13/17
NO CHANGE
Target $28
PIPR
Overweight
Finisar price target raised to $28 after Apple award at Piper Jaffray
Piper Jaffray analyst Troy Jensen raised his price target on Finisar (FNSR) to $28 from $22 after the company was awarded a $390M investment from Apple (AAPL) to scale VCSEL capacity, saying that he believes the deal solidifies a long-term relationship between the companies. Jensen has previously assumed Finisar only had 25% of the high-powered VCSEL for the iPhone X and Lumentum (LITE) had 75% of the high-power and 100% of the low-power VCSEL, but he now believes Finisar could capture significantly more share than previously expected, he tells investors.
12/08/17
CHLM
12/08/17
NO CHANGE
Target $24
CHLM
Buy
Finisar gross margins likely near bottom, says Craig-Hallum
Craig-Hallum analyst Richard Shannon said it could be "a couple more quarters" before Finisar (FNSR) is able to report both meaningful sales and gross margin improvement together. However, he notes that the company is currently guiding its gross margins near levels where they'd previously bottomed twice over the past six years, which indicates to him they may be near a bottom again. Shannon said he is encouraged by the company's apparent 3D sensor qualification, which he believes to be at Apple (AAPL), and maintains a Buy rating on Finisar shares, though he trimmed his price target to $24 from $25.
12/08/17
PIPR
12/08/17
NO CHANGE
Target $22
PIPR
Overweight
Finisar price target lowered to $22 from $26 at Piper Jaffray
Piper Jaffray analyst Troy Jensen lowered his price target for Finisar to $22 saying the company reported mixed October quarter results, with revenues modestly above recently lowered consensus and earnings well below expectations. The analyst likes the setup for Finisar as he expects a "modest" recovery in China, traction with ACO design wins and a meaningful ramp in 3D sensing sales in 2018. He believes the current risk/reward looks attractive and reiterates an Overweight rating on the shares.
12/06/17
STFL
12/06/17
NO CHANGE
Target $23
STFL
Buy
Finisar price target lowered ahead of earnings to $23 at Stifel
Stifel analyst Patrick Newton lowered his Q2 revenue and pro forma EPS estimates for Finisar ahead of the company's upcoming earnings report and cut his price target on the stock to $23 from $27, citing expectations for negative mix shifts, no material rebound in China order trends, and worse than expected 40G revenue due to the shift to 100G. However, he maintain his Buy rating on the shares, saying this is due "largely" to valuation.
AAPL Apple
$171.70

-0.97 (-0.56%)

12/13/17
SBSH
12/13/17
NO CHANGE
Target $200
SBSH
Buy
Citi lists reasons to own Apple despite 48% year-to-date rally
Citi analyst Jim Suva sees five reasons Apple shares can trade higher in 2018 despite the 48% year-to-date rally in 2017. He reiterates a Buy rating on the stock with a $200 price target. The iPhone maker closed yesterday down 97c to $171.70. The "super upgrade cycle" will continue in 2018 as iPhone production issues have resulted in elongated lead times versus prior cycles, Suva tells investors in a research note. This is his number one reason for the stock moving higher next year. The remaining four are tax reform, continued Services revenue growth from a "sticky" user base, more spending from enterprises growth and an "attractive" valuation with Apple trading at a 20% discount to the S&P 500.
12/11/17
RSBL
12/11/17
NO CHANGE
Target $75
RSBL
Buy
Lumentum's shipments could triple in China, says Rosenblatt
Rosenblatt analyst Jun Zhang's research indicates Lumentum's shipments of high and low modules into Chinese OEMs could triple in 2018, offsetting CFP2 declines. Zhang said the ROADM ramp could deliver improved margins which could be incremental to US ROADM growth. Further, the analyst believes VCSEL laser competitors are behind Lumentum in terms of yield rate and quality and expects the company to hold its leading position at Apple when Apple (AAPL) books VCSEL laser capacity for 2018-19 over the next 2-3 months. Zhang rates Lumentum a Buy with a $75 price target.
12/11/17
SBSH
12/11/17
NO CHANGE
SBSH
Citi 'getting more nervous' on semiconductors after Asia trip
Following a trip last week to Asia meeting with companies across the technology supply chain, Citi analyst Christopher Danely says he's "getting more nervous" on the semiconductor sector. While demand from the PC end market remains strong, the NAND market remains weak and data points on Apple's (AAPL) iPhone were mixed, Danely tells investors in a research note. The analyst saw signs of an inventory build and believes upside to consensus estimates is declining. He feels momentum is slowing in the semiconductor space. Danely's top pick is Microchip (MCHP) and he's also Buy-rated on Texas Instruments (TXN), Applied Materials (AMAT), Nvidia (NVDA), Skyworks (SWKS), ON Semiconductor (ON) and Micron (MU). The analyst's checks indicate slower than expected iPhone X and 8 demand but stronger iPhone 7 demand. He views this as bad for Skyworks and Qorvo (QRVO) and good for Analog Devices (ADI).
LLNW Limelight Networks
$4.67

-0.02 (-0.43%)

11/13/17
DADA
11/13/17
NO CHANGE
Target $7
DADA
Buy
Limelight Networks geared for larger content than Akamai, says DA Davidson
DA Davidson analyst Mark Kelleher compares the networking technology at Limelight Networks (LLNW) versus that of Akamai (AKAM), saying that because Limelight is more centrally organized across its 84 data centers, it can deliver information with less internet congestion. Kelleher notes that he recently discussed the contrast with Limelight CFO Sajid Malhotra, who explained that customers are willing to pay more for this type of content delivery relative to Akamai, which places its Content Delivery Network within the data centers of its ISP partners. While Akamai's CDN is more advantageous for smaller content like web pages, Kelleher says the rapid growth in video is quickly creating congestion problems for its network. The analyst has a Buy rating on Limelight Networks, nudging his price target to $7 from $6 based on the company's return to top-line growth, as well as improved operating margins, cash flow, and positive earnings.
10/19/17
COWN
10/19/17
NO CHANGE
Target $6
COWN
Outperform
Limelight Networks price target raised to $6 from $4 at Cowen
Cowen analyst Jonathan Charbonneau raised his price target on Limelight Networks to $6 from $4 following solid Q3 results. The analyst noted the company increased its guidance driven by another quarter of healthy demand with accelerating growth in OTT. He continues to see the stock as undervalued. Charbonneau reiterated his Outperform rating on Limelight Networks shares.
10/19/17
DADA
10/19/17
NO CHANGE
Target $6
DADA
Buy
Network infrastructure to drive Limelight Networks margins, says DA Davidson
DA Davidson analyst Mark Kelleher maintained his Buy rating on Limelight Networks, raising his price target to $6.00 from $5.50 after the company posted its highest Q3 revenue in 19 quarters. Kelleher says new customer wins are laying a foundation for growth this year and beyond, while improvements in Limelight's infrastructure should further boost gross margins, paving the way to new revenue drivers.
10/16/17
DADA
10/16/17
NO CHANGE
Target $5.5
DADA
Buy
Limelight Networks to continue market share gains, says DA Davidson
DA Davidson analyst Mark Kelleher raised his price target on Limelight Networks (LLNW) to $5.50 from $4.50 and maintained his Buy rating ahead of the company's Q3 earnings. Kelleher notes that Limelight is laying a foundation for growth beyond 2017 with new customer wins in numerous vertical markets, and further improvements in its infrastructure will add an upward bias to gross margins next year and beyond. The analyst expects continued market share gains to outpace its largest competitor Akamai Technologies (AKAM), which he expects to show another decline in Media delivery business.
WDC Western Digital
$81.77

0.57 (0.70%)

12/13/17
SMTR
12/13/17
UPGRADE
SMTR
Buy
Western Digital upgraded to Buy from Hold at Summit Redstone
12/13/17
COWN
12/13/17
NO CHANGE
COWN
Outperform
JV settlement positive for both Western Digital and Seagate, says Cowen
Cowen analyst Karl Ackerman said Western Digital's (WDC) settlement agreement with Toshiba (TOSBF) is largely in line with his prior expectations and should lead to a better multiple for Western Digital shares since it removes one of investors' primary fears. The deal is also a positive for Seagate (STX), according to Ackerman, as it gives that company an opportunity to access NAND supply from Toshiba. The analyst, who maintains an Outperform rating on Western Digital, added that the company's updated guidance proves his prior view that Street estimates were "way too low."
12/13/17
EVER
12/13/17
NO CHANGE
Target $130
EVER
Outperform
Western Digital, Toshiba settlement removes large overhang, says Evercore ISI
Evercore ISI analyst C.J. Muse notes that Western Digital (WDC) and Toshiba (TOSBF; TOSYY) announced that they entered into a settlement to resolve their ongoing disputes, with the former also preannouncing positive December quarter results. The analyst sees the news as a "pleasant surprise," removing a large overhang on Western Digital's stock, as investors feared that its NAND supply would be cut off. He reiterates an Outperform rating and $130 price target on Western Digital's shares.
12/13/17
LOOP
12/13/17
NO CHANGE
Target $140
LOOP
Buy
Western Digital gross margins to stabilize in CY18, says Loop Capital
Loop Capital analyst Ananda Baruah reiterates his Buy rating and $140 price target on Western Digital (WDC) "with conviction" after yesterday's formalized agreement with Toshiba (TOSBF) on its flash memory unit sale and upwardly revised guidance. Baruah says the specifics of the Toshiba deal are "very straightforward and amicable", allowing it to continue with its 50% joint investment in all fabs going forward as well as receiving IP sharing restrictions in the sale of the unit to Bain Capital. The analyst also anticipates Western Digital gross margins to stabilize next year, as NAND memory cost reductions in 3D NAND offset the normalizing pricing trends.
PAY Verifone
$18.47

(0.00%)

11/16/17
RAJA
11/16/17
DOWNGRADE
RAJA
Outperform
Verifone downgraded to Outperform from Strong Buy at Raymond James
11/16/17
11/16/17
DOWNGRADE

Outperform
Verifone downgraded to Outperform on slower PoS sales at Raymond James
As previously reported, Raymond James downgraded Verifone to Outperform from Strong Buy and lowered its price target to $22 from $25. Analyst Wayne Johnson is cautious on FY18 Systems Solutions revenue growth and earnings and thinks it will be dominated by older, flagship architecture and said he can not verify traction in its next-generation Carbon and Engage PoS devices, which lack commitment from a large, domestic name brand retailer.
11/16/17
11/16/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Acorda Therapeutics (ACOR) was downgraded to Hold from Buy at Stifel and to Underperform from Market Perform at Raymond James. 2. Verifone (PAY) downgraded to Outperform from Strong Buy at Raymond James with analyst Wayne Johnson saying he is cautious on fiscal 2018 Systems Solutions revenue growth and earnings and thinks it will be dominated by older, flagship architecture and said he can not verify traction in its next-generation Carbon and Engage PoS devices, which lack commitment from a large, domestic name brand retailer. 3. Marriott (MAR) downgraded to Market Perform from Outperform at Bernstein. 4. Emerson (EMR) downgraded to Market Perform from Outperform at Cowen with the firm saying its increased offer for Rockwell (ROK), if accepted, would result in a very low return for years. 5. NetEase (NTES) downgraded to Sell from Underperform at CLSA with analyst Man Ho Lam saying third quarter results were disappointing and expects negative revenue and earnings momentum to continue into the first half of 2018. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/10/17
CHLM
10/10/17
NO CHANGE
CHLM
Green Dot, CPI Card added to Favorite Near-Term Risk/Reward List at Craig-Hallum
Craig-Hallum analyst Brad Berning added Green Dot (GDOT) and CPI Card Group (PMTS) to his Favorite Near-Term Risk/Reward List, saying he expects the former's positive momentum and estimate revisions to continue while believing the current quarter and 4Q outlook can be a positive catalyst for the latter. The analyst also sees positive near-term catalysts for Blackhawk (HAWK), LendingClub (LC), Verifone (PAY) and BofI Holding (BOFI).
MDB MongoDB
$29.00

2.14 (7.97%)

11/13/17
MSCO
11/13/17
INITIATION
Target $31
MSCO
Equal Weight
MongoDB initiated with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Sanjit Singh initiated MongoDB with an Equal Weight rating and $31 price target, saying he sees the company steadily growing share but that its growth prospects are likely already reflected in the stock's current valuation.
12/13/17
ADAM
12/13/17
NO CHANGE
Target $35
ADAM
Buy
MongoDB first report since IPO sets stage for 'breakout' 2018, says Canaccord
Canaccord analyst Richard Davis said MongoDB's results for its first reported quarter post-IPO were "quite good, even adjusting for the wildly conservative guidance that CFOs give." Davis, who predicts that Mongo will "reach escape velocity against its competition" in 2018 on its way to becoming the "de facto NoSQL standard," reiterates a Buy rating and $35 price target on the shares.
12/13/17
NEED
12/13/17
NO CHANGE
NEED
Hold
MongoDB Q3 results driven by Atlas and customer expansion, says Needham
Needham analyst Jack Andrews says MongoDB has posted a "strong" first quarter result as a public company, beating expectations thanks to "momentum at Atlas, broad customer expansion, and continued strength at existing customers." The analyst says he is bullish on the company's near-term fundamentals based on its position as an "emerging industry leader with strong products attacking a huge market opportunity", but keeps his Hold rating, noting that risk-reward is balanced at this point.
11/13/17
11/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Party City (PRTY) assumed with an Overweight at JPMorgan. 2. MongoDB (MDB) was initiated with a Buy at Stifel and Canaccord, an Overweight at Barclays, an Equal Weight at Morgan Stanley, a Market Perform at JMP Securities, and a Neutral at Goldman Sachs. 3. Arista Networks (ANET) initiated with a Neutral at Piper Jaffray. 4. NetScout (NTCT) initiated with an Overweight at Piper Jaffray. 5. Aveo Oncology (AVEO) initiated with a Buy at B. Riley FBR. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
CIVI Civitas Solutions
$19.80

(0.00%)

08/23/17
08/23/17
NO CHANGE

Civitas announces agreement to acquire stock of Habilitative Services and others
Civitas Solutions announced that it has entered into an agreement to acquire the stock of Habilitative Services and two related companies, or HSI, providers of services to individuals with intellectual and developmental disabilities in the state of Minnesota. The agreement is subject to a number of closing conditions, including the expiration of a regulatory notice period. The parties expect to close the transaction within 30-45 days. With more than 1,100 employees, HSI generated revenues of approximately $32.8M for the 12-month period up to and including May.
05/11/17
ADAM
05/11/17
NO CHANGE
Target $26
ADAM
Buy
Civitas Solutions valuation makes stock attractive, says Canaccord
Canaccord analyst Richard Close said the valuation of Civitas Solutions makes its stock attractive. The company is executing on its growth strategy via new starts and M&A while continuing to navigate cost pressure issues, such as labor, occupancy, and healthcare costs. The company reaffirmed its guidance and the rate environment appears stable, said Close, who reiterates his Buy rating and $26 price target on Civitas.
ARWR Arrowhead
$3.55

0.04 (1.14%)

11/27/17
PIPR
11/27/17
UPGRADE
Target $5.5
PIPR
Overweight
Arrowhead upgraded to Overweight from Neutral at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff upgraded Arrowhead Pharmaceuticals to Overweight and raised his price target for the shares to $5.50 from $3. The shares closed Friday up 6c to $3.70. The company intends to file five Clinical Trial Applications on subcutaneous targeted RNAi molecules in 2018, Tenthoff tells investors in a research note. The analyst looks for Arrowhead to create value by generating first in man TRiM clinical data and potentially signing new partnerships.
09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
Arrowhead upgraded to Outperform from Market Perform at William Blair
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform saying the company's analyst day highlighted a "broad" pipeline.
03/03/17
WBLR
03/03/17
NO CHANGE
WBLR
HBV space to consolidate over next five years, says William Blair
William Blair analyst Y. Katherine Xu sees curing chronic hepatitis B virus infections as "the next frontier" after the success of hepatitis C treatments and believes the market for an HBV cure could be "similar in size to that of HCV," or $200B in cumulative global sales over a span of two decades. She expects consolidation of the HBV market over the next five years, much like what happened with the HCV market. Xu sees Spring Bank Pharmaceuticals (SBPH) and Arbutus (ABUS) as having the strongest data catalysts in 2017, followed by Assembly Biosciences (ASMB) and Arrowhead (ARWR). She has Outperform ratings on the first three stocks and a Market Perform rating on Arrowhead.
09/18/17
WBLR
09/18/17
UPGRADE
WBLR
Outperform
William Blair upgrades Arrowhead with $6 fair value estimate
William Blair analyst Y. Katherine Xu upgraded Arrowhead Pharmaceuticals to Outperform from Market Perform and raised her fair value estimate for the shares to $6 from $2. The stock closed Friday up 51c to $3.30. Last week's R&D day revealed the TRiM platform for developing novel RNA interference medicines and promised five investigational new drug or clinical trial application filings in 2018, Xu tells investors in a research note. The analyst highlights "versatility" of the company's TRiM platform for designing decorated RNAi drugs.
LLY Eli Lilly
$86.71

(0.00%)

10/24/17
PIPR
10/24/17
NO CHANGE
Target $107
PIPR
Overweight
Eli Lilly Humalog fears overblown, says Piper Jaffray
Piper Jaffray analyst Richard Purkiss attributes Eli Lilly's (LLY) post-earnings decline to further anxiety around price competition in the U.S. diabetes segment after the company said on its earnings call that it will not challenge Sanofi's (SNY) biosimilar for Humalog. However, he sees these concerns as substantially overdone, pointing to the 39% year-over-year growth reported in Q3 for the diabetes franchise, and view today's pullback as a clear buying opportunity. Purkiss keeps an Overweight rating on Eli Lilly and raised his price target on the stock to $107 from $105.
11/16/17
JEFF
11/16/17
NO CHANGE
JEFF
Buy
Jefferies names Roche new top global pick in Pharmaceuticals
Jefferies analyst Jeffrey Holford names Roche (RHHBY) his new "Top Pick Globally" in Pharmaceuticals following the strong share performance of his previous top pick for 2017, AbbVie (ABBV). The analyst believes the company's growth outlook is better than many investors think. Roche is nearing sentiment lows and investors "need to look hard at the replacement power" offered by assets Tecentriq, Ocrevus, Gazyva, ACE910 and Perjeta, Holford tells investors in a research note. Following Roche, the analyst has the highest conviction on Novartis (NVS), Bayer (BAYRY), AbbVie, Johnson & Johnson (JNJ), Zoetis (ZTS) and Eli Lilly (LLY). His least preferred stocks in Pharmaceuticals are Merck (MRK), Novo Nordisk (NVO) and AstraZeneca (AZN).
11/13/17
BMOC
11/13/17
NO CHANGE
BMOC
BMO says Pfizer buying Biogen makes more sense than deal for Bristol-Myers
BMO Capital analyst Alex Arfaei noted the "significant market speculation" that Pfizer (PFE) is preparing to execute a large M&A deal. While many sources, including Bloomberg, have speculated that Pfizer could target Bristol-Myers (BMY), Arfaei argues that a deal for Biogen (BIIB) would make more sense. He believes Pfizer has a significant gap in neurology, particularly in Alzheimer's, where it cannot afford to remain on the sidelines as its peers - including Biogen, Merck (MRK), AstraZeneca (AZN), and Eli Lilly (LLY) - all have pivotal trials in that area reading out in 2019-2020. Pfizer could have an opportunity to leverage near-term volatility in Biogen's MS franchise to strike a deal during the next 6-9 months before a potential interim look on aducanumab, which Arfaei views as the strongest of the next wave of Alzheimer's drugs in development, he tells investors.
11/21/17
PIPR
11/21/17
NO CHANGE
PIPR
Piper says selection for Lilly 'diabetes ecosystem' a clear positive for Dexcom
Piper Jaffray analyst Matt O'Brien said it was news to him that Eli Lilly (LLY) is developing a diabetes pump and smart pen as part of its "diabetes ecosystem" plans. The company's selection of Dexcom's (DXCM) CGM as part of their integrated system is a clear positive for Dexcom, while Lilly's launch of an integrated system in the U.S. market is a modest negative for Insulet (PODD) and Tandem Diabetes (TNDM) given it will create a competitive headwind starting in 2021, added O'Brien.
AMTD TD Ameritrade
$52.69

0.61 (1.17%)

11/13/17
11/13/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. J.M. Smucker (SJM) upgraded to Positive from Neutral at Susquehanna with analyst Pablo Zuanic saying he believes the rout of food stocks is ebbing and since this company is the worst performing stock in his coverage universe, he chose to play the food trade with it. 2. Delek US (DK) upgraded to Strong Buy from Outperform at Raymond James with analyst Justin Jenkins saying it will benefit from a wider Brent-WTI spread. 3. Nvidia (NVDA) upgraded to Market Perform from Underperform at BMO Capital with analyst Ambrish Srivastava saying the company has demonstrated a "far stronger" data center business than he had forecast and its leverage is greater than anticipated. 4. Praxair (PX) upgraded to Buy from Hold at Argus with analyst Bill Selesky saying the company is well positioned to deliver stronger Earnings Per Share growth thanks to its mix of high-growth businesses driving above-industry-average margins, earnings, and returns on invested capital. 5. TD Ameritrade (AMTD) upgraded to Buy from Hold at Deutsche Bank with analyst Brian Bedell saying trading volumes are improving, trade pricing will hold up better than expected and the Scottrade integration is going very well. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
12/07/17
MSCO
12/07/17
NO CHANGE
MSCO
Morgan Stanley says TD Ameritrade most likely discount broker to embrace bitcoin
Given recent regulatory approval and the upcoming launch of bitcoin futures trading on CME (CME) and CBOE (CBOE), Morgan Stanley analyst Michael Cyprys said he expects discount brokers including E-Trade (ETFC), TD Ameritrade (AMTD) and Ally Financial (ALLY) to offer bitcoin futures trading within the next few months. Among them, he views TD Ameritrade as most likely to embrace bitcoin and lead the way and Charles Schwab (SCHW) as likely to be a latecomer. Cyprys added that he was surprised, given its status as a "challenger brand," that E-Trade has said it will take "a wait-and-see" approach.
11/30/17
FBCO
11/30/17
INITIATION
Target $45
FBCO
Underperform
TD Ameritrade initiated with an Underperform at Credit Suisse
Credit Suisse analyst Craig Siegenthaler started TD Ameritrade with an Underperform rating and $45 price target. The analyst believes the company's "lower quality" revenue sources and continued business mix shift are risks.
11/13/17
DBAB
11/13/17
UPGRADE
Target $55
DBAB
Buy
TD Ameritrade upgraded to Buy from Hold at Deutsche Bank
Deutsche Bank analyst Brian Bedell upgraded TD Ameritrade to Buy and raised his price target for the shares to $55 from $53. Trading volumes are improving, trade pricing will hold up better than expected and the Scottrade integration is going very well, Bedell tells investors in a research note. He believes the recent 5% pullback in TD shares provides a good entry point.
NAT Nordic American Tankers
$3.67

(0.00%)

12/20/16
MAXM
12/20/16
INITIATION
Target $7
MAXM
Sell
Nordic American Tankers initiated with a Sell at Maxim
Maxim initiated Nordic American Tankers with a Sell and a $7 price target.
01/13/17
FBCO
01/13/17
INITIATION
Target $9
FBCO
Neutral
Nordic American Tankers initiated with a Neutral at Credit Suisse
Credit Suisse analyst Gregory Lewis initiated Nordic American Tankers to Neutral with a $9 price target citing near-term headwinds from OPEC production cuts.
12/20/16
MAXM
12/20/16
INITIATION
Target $7
MAXM
Sell
Nordic American Tankers initiated with a Sell at Maxim
Maxim analyst James Jang initiated Nordic American Tankers with a Sell rating and $7 price target, as his asset valuation model implies the stock is trading above its net asset value.
07/21/17
EVER
07/21/17
DOWNGRADE
Target $5
EVER
Underperform
Nordic American Tankers downgraded to Underperform from In Line at Evercore ISI
Evercore ISI analyst Jonathan Chappell downgrade Nordic American Tankers to Underperform and lowered its price target to $5 from $6 saying. The analyst believes the company will not be able to pay a dividend for Q3 after a likely 50% cut for Q2, further pressuring the valuation premium.

TODAY'S FREE FLY STORIES

ADP

ADP

$137.13

-0.19 (-0.14%)

09:33
07/17/18
07/17
09:33
07/17/18
09:33
Initiation
ADP initiated  »

ADP initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

DXC

DXC Technology

$85.74

-0.41 (-0.48%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
DXC Technology initiated  »

DXC Technology initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACN

Accenture

$167.63

-0.48 (-0.29%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Accenture initiated  »

Accenture initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSX

CSX

$63.96

-0.74 (-1.14%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Technical Analysis
Technical Earnings Preview: CSX may have double-topped before news »

On the 1-year, daily…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 26

    Aug

GPN

Global Payments

$117.00

-0.98 (-0.83%)

09:32
07/17/18
07/17
09:32
07/17/18
09:32
Initiation
Global Payments initiated  »

Global Payments initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

TSS

TSYS

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
TSYS initiated  »

TSYS initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

RARE

Ultragenyx

$84.32

-0.23 (-0.27%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Recommendations
Ultragenyx analyst commentary  »

Ultragenyx price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

KTOS

Kratos Defense

$12.85

0.14 (1.10%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Hot Stocks
Kratos Defense receives $8.5M in orders in support of C5 programs »

Kratos Defense announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTSH

Cognizant

$81.97

0.26 (0.32%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Cognizant initiated  »

Cognizant initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

  • 15

    Aug

  • 16

    Aug

LTC

LTC Properties

$41.84

-0.32 (-0.76%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Hot Stocks
LTC Properties acquires two communities for $25.2M »

LTC Properties announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WP

Worldpay

$86.51

(0.00%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Worldpay initiated  »

Worldpay initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

FDC

First Data

$22.24

-0.06 (-0.27%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
First Data initiated  »

First Data initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

BR

Broadridge

$117.70

-0.27 (-0.23%)

09:31
07/17/18
07/17
09:31
07/17/18
09:31
Initiation
Broadridge initiated  »

Broadridge initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

V

Visa

$138.45

-0.91 (-0.65%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
Visa initiated  »

Visa initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

FIVE

Five Below

$103.50

2.1 (2.07%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Recommendations
Five Below analyst commentary  »

Five Below price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MA

MasterCard

$204.05

-1.86 (-0.90%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
MasterCard initiated  »

MasterCard initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

UNH

UnitedHealth

$257.03

-1.69 (-0.65%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Hot Stocks
Breaking Hot Stocks news story on UnitedHealth »

UnitedHealth sees 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

PYPL

PayPal

$87.77

-0.2 (-0.23%)

09:30
07/17/18
07/17
09:30
07/17/18
09:30
Initiation
PayPal initiated  »

PayPal initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 16

    Aug

SBRA

Sabra Health Care

$22.36

-0.17 (-0.75%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Hot Stocks
Sabra, PointRight announce strategic partnership for post-acute analytics »

Sabra Health Care REIT…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECOR

ElectroCore

$14.49

-0.51 (-3.40%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Initiation
ElectroCore initiated  »

ElectroCore initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HRC

Hill-Rom

$91.35

0.03 (0.03%)

09:28
07/17/18
07/17
09:28
07/17/18
09:28
Recommendations
Hill-Rom analyst commentary  »

Hill-Rom price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

  • 14

    Aug

  • 15

    Aug

PM

Philip Morris

$81.91

-0.78 (-0.94%)

09:26
07/17/18
07/17
09:26
07/17/18
09:26
Recommendations
Philip Morris analyst commentary  »

Philip Morris estimates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Jul

NFLX

Netflix

$400.24

4.32 (1.09%)

09:25
07/17/18
07/17
09:25
07/17/18
09:25
Recommendations
Netflix analyst commentary  »

Netflix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
U.S. industrial production bounced 0.6% in June »

U.S. industrial…

09:25
07/17/18
07/17
09:25
07/17/18
09:25
General news
FX Action: The dollar »

FX Action: The dollar was…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.